Literature DB >> 28439496

Bethesda System for Reporting Thyroid Cytopathology: A three-year study at a tertiary care referral center in Saudi Arabia.

Mohamed Abdulaziz Al Dawish1, Asirvatham Alwin Robert1, Aljuboury Muna1, Alkharashi Eyad1, Abdullah Al Ghamdi1, Khalid Al Hajeri1, Mohammed A Thabet1, Rim Braham1.   

Abstract

AIM: To stratify the malignancy risks in thyroid nodules in a tertiary care referral center using the Bethesda system.
METHODS: From January, 2012 to December, 2014, a retrospective analysis was performed among 1188 patients (15-90 years) who had 1433 thyroid nodules and fine-needle aspiration at Prince Sultan Military Medical City, Saudi Arabia. All thyroid cyto-pathological slides and ultra sound reports were reviewed and classified according to the Bethesda System for Reporting Thyroid Cytopathology. Age, gender, cytological features and histological types of the thyroid cancer were collected from patients' medical chart and cytopathology reports.
RESULTS: There were 124 total cases of malignancy on resection, giving an overall surgical yield malignancy of 33.6%. Majority of the thyroid cancer nodules (n = 57, 46%) in Bethesda VI category followed by Bethesda IV (n = 25, 20.2%). Almost 40% of the cancer nodules in 31-45 age group in both sex. Papillary thyroid carcinoma (PTC) was the most common form of thyroid cancer among the study population (111, 89.6%) followed by 8.9% of follicular thyroid carcinoma (FTC), 0.8% of medullary carcinoma and 0.8% of anaplastic carcinoma. Among the Bethesda IV category 68% thyroid nodules were PTC and 32% FTC.
CONCLUSION: The malignancy values reported in our research were constant and comparable with the results of other published data with respect to the risk of malignancy. Patients with follicular neoplasm/suspicious for follicular neoplasm and suspicious of malignancy categories, total thyroidectomy is indicted because of the substantial risk of malignancy.

Entities:  

Keywords:  Bethesda; Fine needle aspiration; Risk of malignancy; Thyroid nodules; Total thyroidectomy

Year:  2017        PMID: 28439496      PMCID: PMC5385436          DOI: 10.5306/wjco.v8.i2.151

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


Core tip: The purpose of this study was to stratify the malignancy risks in thyroid nodules in a tertiary care referral center using the Bethesda system. The study found that there were 124 total cases of malignancy on resection, giving an overall surgical yield malignancy of 33.6%. Majority of the thyroid cancer nodules in Bethesda VI category followed by Bethesda IV. Almost 40% of the cancer nodules in 31-45 age group in both sex. Papillary Thyroid Carcinoma was the most common form of thyroid cancer among the study population followed by follicular thyroid carcinoma, medullary carcinoma and anaplastic carcinoma.

INTRODUCTION

According to epidemiological and clinical studies thyroid nodules are commonly encountered in clinical exams, palpable in 5% of the population on thyroid examination and detectable in nearly 60% of those subjected to thyroid ultrasound. While the majority of the nodules are benign (non-cancerous), they are normally the first indicators of thyroid cancer; therefore, further investigations are required to identify the cancerous nodule[1,2]. The last decades have revealed a constant and remarkable rise in the occurrence of thyroid cancer across the world, including Saudi Arabia[3-5]. The Saudi Cancer Registry (SCR) report has registered 890 thyroid cancer cases, in nearly 8.1% of all the newly diagnosed cases in 2012. However, studies revealed variations in the incidence of thyroid cancer globally. Thyroid cancer is the 5th most common cancer among females in the United States, whereas in Saudi Arabia it is the 2nd commonest identified cancer in females, and 8th among males[6]. However, compared with the developed countries, research regarding the malignancy risks in thyroid nodules is still insufficient due to lack of appropriate studies being conducted in these specified areas. One of the most widely used diagnostic tools is fine-needle aspiration (FNA) cytology with ultrasound imaging to determine the necessity for the surgical excision of a thyroid nodule. Today, molecular genetic biomarker analyses are employed to increase the diagnostic accuracy of the FNA biopsies, and can at times drastically change clinical decision procedures as they become more commonly available and better assessed. FNA cytology (FNAC) continues to remain the initial investigation mode for malignancy in patients with thyroid nodules and the selection of patients for thyroid surgery[7]. This minimally invasive and useful method is highly effective in identifying a large percentage of thyroid nodules as benign and eliminating unnecessary surgery for patients with benign disease[8]. However, because a standardized reporting system is still unavailable, pathologists have been employing varying terminologies and diagnostic criteria, thus causing misunderstanding among the referring clinicians while interpreting cytopathology reports, resulting in non-definitive clinical management[9-11]. In 2007, the National Cancer Institute (NCI) established guidelines employing a standardized nomenclature to interpret thyroid FNAs called the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) which is now accepted as the proposed diagnostic categories for thyroid cancer[12]. This study attempts to stratify the malignancy risks in thyroid nodules in a tertiary care referral center in Saudi Arabia utilizing the Bethesda system.

MATERIALS AND METHODS

Study design and setting

From January, 2012 to December, 2014 (36 mo), a retrospective analysis was performed among 1188 patients (15-90 years old) who had 1433 thyroid nodules and FNA at Prince Sultan Military Medical City (PSMMC), a 1200 bedded tertiary care center, Riyadh, Saudi Arabia. The PSMMC caters to the patients referred from different regions of Saudi Arabia and considered a worthy representative of Saudi Arabia in general. The study protocol was approved by the Research and Ethics Committee of PSMMC, Riyadh, Saudi Arabia.

Data collection

All thyroid cytopathological slides and ultra sound reports were reviewed and classified according to the BSRTC system. Age, gender, cytological features and histological types of the study population were collected from patients’ medical chart and cyto-pathology reports.

Bethesda system

Currently, the Bethesda system of reporting thyroid cytology (TBSRTC) is used for reporting FNAC specimens of thyroid. According to Cibas[13], this system was innovated in 2007 and consists of six categories: (1) Unsatisfactory (UNS) or nondiagnostic (ND); (2) Benign and nonneoplastic; (3) Atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS); (4) Follicular neoplasm or suspicious for follicular neoplasm (FNS/SFN); (5) Suspicious for, but not diagnostic of, malignancy; and (6) Malignant (Table 1).
Table 1

The Bethesda system

Diagnostic categoryCytological diagnosisRisk of malignancy, %Usual management
INondiagnostic or unsatisfactory1-4Repeat FNA with ultrasound guidance
IIBenign0-3Clinical follow-up
IIIAUS/FLUS5-15Repeat FNA
IVFNS/SFN15-30Surgical lobectomy
VSuspicious for malignancy60-75Near-total thyroidectomy or surgical
VIMalignant97-99Near-total thyroidectomy

FNA: Fine-needle aspiration; AUS/FLUS: Atypia of undetermined significance or follicular lesion of undetermined significance; FNS/SFN: Follicular neoplasm or suspicious for follicular neoplasm.

The Bethesda system FNA: Fine-needle aspiration; AUS/FLUS: Atypia of undetermined significance or follicular lesion of undetermined significance; FNS/SFN: Follicular neoplasm or suspicious for follicular neoplasm. All FNAs were performed by one of five interventional radiologists under ultrasound (US) guidance, performing 3-5 passes by using 25 gauge needles. On-site FNAs stained with the Diff-Quik stain and adequacy assessment was performed for all samples. All slides interpreted by among of five accredited cyto-pathologists.

Histological diagnoses

The histological diagnoses of thyroid nodules were classified into two types: Benign and nonneoplastic and malignant. For papillary thyroid carcinoma (PTC), subtype variants were documented such as the follicular variant, classical variant, conventional variant and tall cell variant. Also were follicular thyroid carcinoma (FTC) subdivided to minimally invasive follicular thyroid carcinoma (MIFTC) and Widely Invasive follicular thyroid carcinoma (WIFTC).

Statistical analysis

All statistical calculations were performed using IBM SPSS Statistics (IBM SPSS Statistics for Windows, Version 22, SPSS Inc. an IBM Company) program and Microsoft Excel 2010 (Microsoft Corporation, Seattle, WA, United States). The descriptive analysis of the epidemiological data presented as frequencies, percentages and mean ± standard deviation (SD). χ2 test was performed to find out the variables associated with cancer among the surgical patients.

RESULTS

A total of 1188 patients (range 15-90 years) included in this study. The mean age of the study population was 46.3 ± 15.1 (SD), median 45 years, and mode 49 years. Of the 1188 (212 male; 976 female) patients, 245 patients had two thyroid nodules, which resulted in a total of 1433 FNA cases (nodules). Among the study population, a total of 311 patients underwent surgery and 877 patients did not undergo surgery. Of the 311 patients who underwent surgery, 58 patients had two thyroid nodules, which resulted in a total of 369 cases (245 benign and 124 malignant) (Figure 1). Among patients who underwent surgery, no statistically significant differences were observed on the presence of cancer among both gender (P = 0.463), and different age groups (P = 0.928).
Figure 1

Flowchart of thyroid nodules description among 1188 patients and the risk of malignancy among 311 surgically excised nodules during January, 2012 to December, 2014. FNA: Fine needle aspiration.

Flowchart of thyroid nodules description among 1188 patients and the risk of malignancy among 311 surgically excised nodules during January, 2012 to December, 2014. FNA: Fine needle aspiration. As shown in Table 2, the distribution of all cases in the six Bethesda diagnostic categories were as follows: 46 cases (3.2%) of category I, 1080 cases (75.3%) of category II, 131 cases (9.1%) of category III, 71 cases (5%) of category IV, 32 cases (2.2%) of category V and 73 cases (5.1%) of category VI.
Table 2

Age and sex distribution of thyroid lesion (based on fine-needle aspiration cytology according to Bethesda system)

Age (yr)Total number of patientsGenderAll FNAs (n = 1433) n, %
F/MBethesda IBethesda IIBethesda IIIBethesda IVBethesda VBethesda VITotal
15-30176 (14.8)159/179 (4.5)149 (74.9)17 (8.5)12 (6)4 (2)8 (4)199
31-45420 (35.4)362/5812 (2.4)375 (74.7)41 (8.2)28 (5.6)14 (2.8)32 (6.4)502
46-60374 (31.5)301/7315 (3.3)347 (75.1)40 (8.8)22 (4.8)9 (2)23 (5)456
61-75175 (14.7)126/4910 (4.5)162 (72.3)33 (14.7)7 (3.1)4 (1.8)8 (3.6)224
> 7543 (3.6)28/15047 (90.4)02 (3.8)1 (1.9)2 (3.8)52
Total1188976/21246 (3.2)1080 (75.3)131 (9.1)71 (5)32 (2.2)73 (5.1)1433

FNA: Fine-needle aspiration; F: Female; M: Male.

Age and sex distribution of thyroid lesion (based on fine-needle aspiration cytology according to Bethesda system) FNA: Fine-needle aspiration; F: Female; M: Male. The distributions of follow-up diagnoses for each initial Bethesda diagnostic classification are shown in Table 3. There were 124 total cases of malignancy on resection, giving an overall surgical yield of malignancy of 33.6%. Eight of (2.2%) 369 thyroid nodules were diagnosed as ND, 181 (49.1%) diagnosed as benign, 42 (11.4%) diagnosed as AUS/FLUS, 53 (14.4%) as FNS/SFN. Category V (SM) diagnoses (26 cases) reminded benign in 8 cases, but histologically confirmed as carcinoma in 18 case (69.2%). Finally, category VI diagnoses (59 cases) reminded benign in 2 cases, but histologically confirmed as carcinoma in 57 cases (96.7%).
Table 3

Cyto-Histopathological correlation of thyroid lesion

CytopathologyHistopathological diagnosis
Total
BenignMalignant, n (%)
Bethesda I62 (25)8
Bethesda II16516 (8.9)181
Bethesda III366 (14.3)42
Bethesda IV2825 (47.2)53
Bethesda V818 (69.3)26
Bethesda VI257 (96.7)59
Total245124 (33.6)369
Cyto-Histopathological correlation of thyroid lesion Table 4 shows the comparison rates of malignancy on surgical resection for FNA diagnostic categories and malignancy risk of the present findings and previously published data. Table 5 shows the age and sex distribution of thyroid cancer. Majority of the thyroid cancer nodules (n = 57, 46%) in Bethesda VI category followed by Bethesda IV (n = 25, 20.2%) and Bethesda V (n = 18, 14.5%). Among the Bethesda IV category 17 (68%) were PTC and 8 (32%) were follicular carcinoma. Almost 40% of the cancer nodules in 31-45 age groups in both sex.
Table 4

Comparison rates of malignancy (%) on surgical resection for fine-needle aspiration diagnostic categories and malignancy risk of recent studies

Published yearComparison of diagnostic categories
I (ND)II (Benign)III (AUS/FLUS)IV (FN/SFN)V (SM)VI (malignant)
Recent studies
Park et al[22]201413.340.69.10.419.317.6
Mondal et al[10]20131.287.514.21.44.7
Mufti et al[29]201211.677.60.842.43.6
Wu et al[30]201220.13927.28.42.62.7
Bongiovanni et al[31]2012254.76.325.36.35.4
Present study3.275.39.152.25.1
Comparison of malignancy risk
Haugen et al[32] (meta-analysis)20169-321-106-4814-3453-9794-100
Pantola et al[33] 20162016008.310100100
Park et al[22]201435.35.6695038.798.9
Mondal et al[10]201304.52030.67597.8
Mufti et al[29]2012203.1502080100
Wu et al[30]2012128273368100
Present study258.914.347.269.396.7

ND: Nondiagnostic; AUS/FLUS: Atypia of undetermined significance/follicular lesion of undetermined significance; FN/SFN: Follicular neoplasm/suspicious for follicular neoplasm; SM: Suspicious for malignancy.

Table 5

Age and sex distribution of thyroid cancer

Age (yr)Total number of nodulesGenderAll FNAs (n = 124) n, %
F/MBethesda IBethesda IIBethesda IIIBethesda IVBethesda VBethesda VI
15-3018 (14.5)3/15031347
31-4549 (39.5)39/101529725
46-6043 (34.7)35/81739518
61-7512 (9.7)8/4010326
> 752 (1.6)2/0000101
Total12487/372 (1.6)16 (12.9)6 (4.8)25 (20.2)18 (14.5)57 (46)

FNA: Fine-needle aspiration; F: Female; M: Male.

Comparison rates of malignancy (%) on surgical resection for fine-needle aspiration diagnostic categories and malignancy risk of recent studies ND: Nondiagnostic; AUS/FLUS: Atypia of undetermined significance/follicular lesion of undetermined significance; FN/SFN: Follicular neoplasm/suspicious for follicular neoplasm; SM: Suspicious for malignancy. Age and sex distribution of thyroid cancer FNA: Fine-needle aspiration; F: Female; M: Male. Type and variants of thyroid cancer among histopathological diagnosis are shown in Table 6. Papillary carcinoma was the most common form of thyroid cancer among the study population (111, 89.6%). Among PTC (n = 111), four histologic variants exist, with classic variant PTC accounting for 51.4% of PTC followed by follicular-variant PTC (30.6%). Furthermore, 8.9% of malignancies were FTC (including 0.8% of the highest risk widely invasive phenotype), 0.8% of medullary thyroid carcinoma (MTC) and 0.8% of anaplastic thyroid carcinoma (ATC). Among the Bethesda IV category 17 (68%) thyroid nodules were PTC and 8 (32%) were FTC.
Table 6

Type and variants of thyroid cancer among histopathological diagnosis

Type of cancerTotal = 124 (n, %)BETHESDA (n, %)
IIIIIIIV (n = 25)VVI
PTC
Classic variant571513839
Follicular variant341821166
Conventional19022339
Tall-cell variant1000001
Total PTC111 (89.6)215517 (68)1755
FTC
MIFTC10011710
WIFTC1000100
Total FTC11 (8.9)0118 (32)10
MTC1 (0.8)000001
ATC1 (0.8)000001

PTC: Papillary thyroid carcinoma; MTC: Medullary thyroid carcinoma; ATC: Anaplastic thyroid carcinoma; FTC: Follicular thyroid carcinoma; MIFTC: Minimally invasive follicular thyroid carcinoma; WIFTC: Widely invasive follicular thyroid carcinoma.

Type and variants of thyroid cancer among histopathological diagnosis PTC: Papillary thyroid carcinoma; MTC: Medullary thyroid carcinoma; ATC: Anaplastic thyroid carcinoma; FTC: Follicular thyroid carcinoma; MIFTC: Minimally invasive follicular thyroid carcinoma; WIFTC: Widely invasive follicular thyroid carcinoma.

DISCUSSION

Over the last few decades thyroid cancer has been on the rise considerably, globally, while mortality has steadily dropped, including in Saudi Arabia[14]. This reduction in the mortality resulting from thyroid cancer reflects the variations in the exposure to risk factors and alters the diagnosis and treatment of the disease, while the rise in the incidence is probably due to the improvement in the identification of this neoplasm[14]. However, in comparison with the developed countries, research on the incidence, prevalence and type of thyroid cancer in Saudi Arabia is still inadequate due to the lack of suitable studies being done on this specific aspect. Therefore, the objective of the current study is to stratify the risk of malignancy in the thyroid nodules based on the Bethesda system, which enhances the interpretation of the FNAC reports and enables a more accurate study and diagnosis of such thyroid nodules[13,15]. In this study, the distribution of age and gender among the patients is almost similar to those recorded in identical studies[1,2,16]. Besides, the female/male ratio reported in this study for thyroid cancer (4.7:1) concurs with the concept that thyroid cancer occurs more commonly among women. In the present study we found that the overall malignant rate was 33.6% which exactly matches the percentage (33.8%) of 25445 thyroid FNAs used in the meta-analysis done by Bongiovanni et al[17], as well as Jo et al[18] who reported 30.9%. However, this high malignancy rate is not unusual if it is understood that the FNAC is consistently being performed today for most patients with thyroid nodules. This has resulted in a drop in the number of unwarranted surgeries and thereby to an increase in the percentage for reported malignancies[1]. It is noteworthy that the number of FNA cases in this study steadily rose from 2012 (n = 357) to 2014 (n = 449). From various studies it was evident that the percentage of cases that were subjected to surgery differed widely among different institutions, reporting a range from 11.8%[19] to 45.1%[20] with an average rate of 25%[17]; the current study identified 26.2% of the study population who had surgical outcome. Each Bethesda category showed a malignancy rate ranging from 1%-10% (“benign category) to 94%-100% (“malignant” category). This comprehensive range highlights the ability of the Bethesda system to differentiate and determine the likelihood of malignancy. The results recorded in our research concurred closely with the results reported in the American Thyroid Association Management Guidelines and other studies: 25% vs 9%-32% (“non-diagnostic or unsatisfactory” category), 9.3% vs 1%-10% (“benign and non-neoplastic” category), 14.3% vs 6%-48% (AUS/FLUS), 69.2% vs 53%-97% (“suspicious for malignancy” category), and 96.7% vs 94%-100% (“malignant” category)[13,17]. Among Bethesda, category IV found 47.2% malignancy risk, a value higher than the meta-analysis results of 14%-34% (FNS/SFN), published recently by Bongiovanni et al[17]. However, many studies revealed the greatest variation in the risk of malignancy class IV, some of which are higher (malignancy rate 50%-67%) than the present values[21-23]. The current study reported PTC (89.6%) as the commonest type of thyroid cancer in the population under study. Studies also reported that overall PTC as the commonest kind of thyroid cancer represents 80% of all the thyroid malignancies and more than 90% of the differentiated thyroid cancers[13,24,25]. A spurt in the occurrence of PTC over the past decades has triggered greater interest in this disease. This is one of the fastest growing kinds of cancer recording over 20000 new cases annually. Although individuals are susceptible to papillary carcinoma irrespective of age, most patients will show the disease prior to 45 years of age[26], a fact corroborated by the current findings (42% PTC between 31-45 years of age). Unfortunately, FTC is not being diagnosed as often, although there is an increasing incidence of well-differentiated thyroid carcinomas everywhere else[27,28], concurring with the results of the current study. There are a two limitations to this study, mainly the retrospective design and performance in a single center. As the PSMMC is a tertiary center for thyroid lesions, the data of this study may not precisely reflect the general population. More research is warranted to overcome the limitations of the study. In conclusion, 33.6% of the cases overall among the surgically excised nodules, showed malignancy. The malignancy values reported in our research were constant and comparable with the results of other data with respect to the risk of malignancy. For the FN/SF patients and those with suspicions of malignancy, total thyroidectomy is indicated because of the substantial risk of malignancy. It is clear, that reviewing the thyroid FNAs with the Bethesda system allowed a more precise cytological diagnosis. However, the impact of Bethesda application may vary among different institutions. Clinicians are advised to be aware of the malignancy rate in the Bethesda categories in their respective institutions to improve the investigation and decision regarding patients with thyroid nodules.

COMMENTS

Background

The National Cancer Institute, United States, established guidelines employing a standardized nomenclature to interpret thyroid fine-needle aspirations (FNAs) called the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) which is now accepted as the proposed diagnostic categories for thyroid cancer.

Research frontiers

Compared with the developed countries, research regarding the malignancy risks in thyroid nodules is still inadequate due to lack of appropriate studies being conducted in these specified areas in Saudi Arabia. Hence, this present study attempts to stratify the malignancy risks in thyroid nodules in a tertiary care referral center in Saudi Arabia utilizing the Bethesda system.

Innovations and breakthroughs

The study found that there were 124 total cases of malignancy on resection, giving an overall surgical yield malignancy of 33.6%. Majority of the thyroid cancer nodules in Bethesda VI category followed by Bethesda IV. Almost 40% of the cancer nodules in 31-45 age group in both sex. Papillary thyroid carcinoma was the most common form of thyroid cancer among the study population followed by follicular thyroid carcinoma, medullary carcinoma and anaplastic carcinoma.

Applications

Reviewing the thyroid FNAs with the Bethesda system allowed a more precise cytological diagnosis. However, the impact of Bethesda application may vary among different institutions. Clinicians are advised to be aware of the malignancy rate in the Bethesda categories in their respective institutions to improve the investigation and decision regarding patients with thyroid nodules.

Terminology

PTC: Papillary thyroid carcinoma; FTC: Follicular thyroid carcinoma; SCR: Saudi Cancer Registry; FNA: Fine-needle aspiration; FNAC: Fine-needle aspiration cytology; NCI: National Cancer Institute, United States; BSRTC: Bethesda System for Reporting Thyroid Cytopathology; PSMMC: Prince Sultan Military Medical City; TBSRTC: The Bethesda system of reporting thyroid cytology; UNS: Unsatisfactory; ND: Nondiagnostic; AUS/FLUS: Atypia of undetermined significance or follicular lesion of undetermined significance; US: Ultrasound; MIFTC: Minimally invasive follicular thyroid carcinoma; WIFTC: Widely Invasive follicular thyroid carcinoma; ATC: Anaplastic thyroid carcinoma.

Peer-review

The study shows a very exhaustive analysis of the throughput of thyroid cytopathology over a three-year period. The manuscript contains a detailed exposition of the results, including comprehensive tables and a comparison to other recent studies. In my opinion, this manuscript fulfills all the requirements to be published.
  30 in total

1.  Diagnostic accuracy of surgeon-performed ultrasound-guided fine-needle aspiration of thyroid nodules.

Authors:  Linda Bohacek; Mira Milas; Jamie Mitchell; Allan Siperstein; Eren Berber
Journal:  Ann Surg Oncol       Date:  2011-06-02       Impact factor: 5.344

2.  Thyroid cancer pooled analysis from 14 case-control studies: what have we learned?

Authors:  Susan Preston-Martin; Silvia Franceschi; Elaine Ron; Eva Negri
Journal:  Cancer Causes Control       Date:  2003-10       Impact factor: 2.506

3.  The role of liquid-based cytology in the investigation of thyroid lesions.

Authors:  M Stamataki; D Anninos; E Brountzos; J Georgoulakis; J Panayiotides; Z Christoni; G Peros; P Karakitsos
Journal:  Cytopathology       Date:  2007-11-06       Impact factor: 2.073

4.  The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution.

Authors:  Constantine G A Theoharis; Kevin M Schofield; Lynwood Hammers; Robert Udelsman; David C Chhieng
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Vickie Y Jo; Edward B Stelow; Simone M Dustin; Krisztina Z Hanley
Journal:  Am J Clin Pathol       Date:  2010-09       Impact factor: 2.493

6.  Diagnostic accuracy of fine needle aspiration cytology in thyroid lesions.

Authors:  E A Sinna; N Ezzat
Journal:  J Egypt Natl Canc Inst       Date:  2012-02-25

Review 7.  Epidemiology of thyroid cancer: a review with special reference to Gulf Cooperation Council (GCC) states.

Authors:  A S Al-Zahrani; K Ravichandran
Journal:  Gulf J Oncolog       Date:  2007-07

8.  Incidence and malignancy rates of diagnoses in the bethesda system for reporting thyroid aspiration cytology: an institutional experience.

Authors:  Ji Hye Park; Sun Och Yoon; Eun Ju Son; Hye Min Kim; Ji Hae Nahm; SoonWon Hong
Journal:  Korean J Pathol       Date:  2014-04-28

9.  Cytological diagnosis of pediatric thyroid nodule in perspective of the Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Chayanika Pantola; Sanjay Kala; Lubna Khan; Saurabh Pantola; Mahendra Singh; Sumanlata Verma
Journal:  J Cytol       Date:  2016 Oct-Dec       Impact factor: 1.000

10.  Diagnostic efficacy and importance of fine-needle aspiration cytology of thyroid nodules.

Authors:  Asli Muratli; Nilsen Erdogan; Sezgin Sevim; Isik Unal; Serap Akyuz
Journal:  J Cytol       Date:  2014-04       Impact factor: 1.000

View more
  8 in total

1.  The diversities in thyroid cytopathology practices among Asian countries using the Bethesda system for reporting thyroid cytopathology.

Authors:  Truong Phan Xuan Nguyen; Vien Thanh Truong; Kennichi Kakudo; Huy Gia Vuong
Journal:  Gland Surg       Date:  2020-10

2.  Indian experience of AUS/FLUS diagnosis: is it different from rest of Asia and the West?-A systematic review and meta-analysis.

Authors:  Prerna Guleria; Kalaivani Mani; Shipra Agarwal
Journal:  Gland Surg       Date:  2020-10

3.  Classification of thyroid fine-needle aspiration cytology into Bethesda categories: An institutional experience and review of the literature.

Authors:  Safa Alshaikh; Zainab Harb; Eman Aljufairi; S Ali Almahari
Journal:  Cytojournal       Date:  2018-02-16       Impact factor: 2.091

4.  Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.

Authors:  Mohamed Al Dawish; Asirvatham Alwin Robert; Khalid Al Shehri; Salwa Hawsawi; Muhammad Mujammami; Ibrahim Ali Al Basha; Mohannad Alrasheed; Shuaa Asiri; Muneerah Alzouman; Eyad Alkharashi
Journal:  Cureus       Date:  2020-05-19

5.  Histopathological Review of Diagnostic Categories of the Bethesda System for Reporting Thyroid Cytopathology - An Institutional Experience of 5 Years.

Authors:  Paricha Upadhyaya; Sushil Dhakal; Purbesh Adhikari; Bindu Adhikari; Dibika Khadka; Surya R Niraula
Journal:  J Cytol       Date:  2019 Jan-Mar       Impact factor: 1.000

6.  Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective.

Authors:  Adnan Zahid; Waqas Shafiq; Khawaja Shehryar Nasir; Asif Loya; Syed Abbas Raza; Sara Sohail; Umal Azmat
Journal:  J Clin Transl Endocrinol       Date:  2021-01-29

7.  Thyroid cancer among patients with thyroid nodules in Yemen: a three-year retrospective study in a tertiary center and a specialty clinic.

Authors:  Butheinah A Al-Sharafi; Jamila A AlSanabani; Ibraheem M Alboany; Amani M Shamsher
Journal:  Thyroid Res       Date:  2020-06-06

8.  Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy.

Authors:  Mohamed Abdulaziz Al Dawish; Asirvatham Alwin Robert; Mohammed A Thabet; Rim Braham
Journal:  Cancer Inform       Date:  2018-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.